Tone mix
Week by week 50 weeks
Share of Palisade Bio, Inc. Common Stock's 84 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Sep 15, 2025 · tone -94Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum-135
- Week of Aug 17, 2026 · tone -100Palisade Bio FY2030 EPS Reduced by Brookline Capital Markets-105
- Week of Sep 21, 2026 · tone +100Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance+92
- Week of Mar 16, 2026 · tone +100Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC Patients+88
- Week of Oct 6, 2025 · tone +100Biotech Stocks Surge After Hours: PCSA, PALI, And QTTB Lead On Volume And Speculation+84
- Week of May 11, 2026 · tone -33Palisade Bio (NASDAQ:PALI) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS-82
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Palisade Bio, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 6 | +33 |
| Last 30 sessions | 13 | +31 |
| Last 90 sessions | 33 | +18 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Wednesday, October 28, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletPalisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative ColitisPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis | www.manilatimes.net | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 27, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletGSK (NYSE:GSK) vs. Palisade Bio (NASDAQ:PALI) Financial ReviewNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| GSK (NYSE:GSK) vs. Palisade Bio (NASDAQ:PALI) Financial Review | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 26, 2026
3 headlines, average tone 0: 0 positive, 3 neutral and 0 negative. Showing all 3.
- www.dailypolitical.com · 1 outletAnalyzing Indivior (NASDAQ:INDV) and Palisade Bio (NASDAQ:PALI)Neutral
- www.themarketsdaily.com · 1 outletCritical Survey: Nexentis Technologies (NASDAQ:NXTS) versus Palisade Bio (NASDAQ:PALI)Neutral
- www.dailypolitical.com · 1 outletWeekly Analysts' Ratings Changes for Palisade Bio (PALI)Neutral
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Analyzing Indivior (NASDAQ:INDV) and Palisade Bio (NASDAQ:PALI) | www.dailypolitical.com | 1 | Neutral |
| Critical Survey: Nexentis Technologies (NASDAQ:NXTS) versus Palisade Bio (NASDAQ:PALI) | www.themarketsdaily.com | 1 | Neutral |
| Weekly Analysts' Ratings Changes for Palisade Bio (PALI) | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 21, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.rttnews.com · 1 outletPalisade Bio Rises 9% As PALI-2108 Shows Early Activity In Crohn's DiseasePositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Palisade Bio Rises 9% As PALI-2108 Shows Early Activity In Crohn's Disease | www.rttnews.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 20, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletPalisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026 | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Palisade Bio, Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.